Spyre Therapeutics (SYRE) Leases (2019 - 2023)
Spyre Therapeutics posted quarterly Leases of $2.3 million for Q2 2023, down 35.93% year-on-year from $3.6 million in Q2 2022, and down 29.09% on a QoQ basis from $3.3 million in Q1 2023.
Spyre Therapeutics (SYRE) has 5 years of Leases data on file, last reported at $2.3 million in Q2 2023.
- For the quarter ending Q2 2023, Leases fell 35.93% year-over-year to $2.3 million; the trailing twelve-month figure through Jun 2023 stood at $2.3 million (down 35.93% YoY), and the FY2022 full-year result was $3.4 million, down 9.88% from the prior year.
- Leases for Q2 2023 stood at $2.3 million, down from $3.3 million in the prior quarter.
- Across five years, Leases topped out at $5.0 million in Q2 2019 and bottomed at $78000.0 in Q1 2019.
- The 5-year median for Leases is $4.0 million (2021), against an average of $3.8 million.
- The widest annual swing landed in 2020, when Leases jumped 5941.03%; it then slumped 35.93% in 2023.
- A 5-year view of Leases shows it stood at $4.7 million in 2019, then declined by 10.5% to $4.2 million in 2020, then fell by 10.02% to $3.8 million in 2021, then dropped by 9.88% to $3.4 million in 2022, then slumped by 32.48% to $2.3 million in 2023.
- The last three Leases figures came in at $2.3 million (Q2 2023), $3.3 million (Q1 2023), and $3.4 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 3.27 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 3.51 Mn |
| Jun 30, 2022 | 3.62 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 3.90 Mn |
| Jun 30, 2021 | 4.01 Mn |
| Mar 31, 2021 | 4.12 Mn |
| Dec 31, 2020 | 4.23 Mn |
| Sep 30, 2020 | 4.39 Mn |
| Jun 30, 2020 | 4.56 Mn |
| Mar 31, 2020 | 4.71 Mn |
| Dec 31, 2019 | 4.73 Mn |
| Sep 30, 2019 | 4.87 Mn |
| Jun 30, 2019 | 5.02 Mn |
| Mar 31, 2019 | 78,000.00 |